Fig. 6

Effects of central recombinant CTRP4 on NF-κB signaling, proinflammatory factors, and microglial activation (BV-2 cells). BV-2 cells were pretreated with DMEM or 2.5 μg/ml, 5 μg/ml, or 10 μg/ml recombinant murine CTRP4 protein for 2 h, followed by 100 μM palmitate or DMSO for 24 h before further analysis. (a, c, e, g, k, m) Representative immunoblots showing CD11b (a), p-P65 and P65 (c), p-IKKα/β and IKKα/β (e), p-IκBα (g), TNF-α (k), and IL-6 (m) in BV-2 cells. (b, d, f, h, l, n) Quantitative analysis of CD11b (b), p-P65 (d), p-IKKα/β (f), p-IκBα (h), TNF-α (l), and IL-6 (n) protein. (i-j) BV-2 cells were pretreated with 10 μg/ml recombinant murine CTRP4 protein or DMEM for 2 h, followed by 100 μM palmitate for 24 h before immunofluorescence analysis. (i) Representative images of P65 immunoreactivity (red) and DAPI nuclear staining (blue) in BV-2 cells. (j) Quantitative analysis of the results in panel i. n = 5 per group. One-way analysis of variance (ANOVA) and Tukey’s test for multiple comparisons were used to analyze differences among groups. ^#P<0.05, ^##P<0.01 vs. the control group, *P<0.05, **P<0.01 vs. PA group